Crestwood, Kentucky -- Apellis Pharmaceuticals has garnered $6 million in venture capital equity investment, according to an SEC regulatory filing.
Apellis is developing peptide drugs focused on the immunology space and in the area of severe asthma and chronic obstructive pulmonary disease..
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
Apellis is still seeking $2 million in additional equity financing, according to the filing. |